JP2017533910A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533910A5
JP2017533910A5 JP2017522852A JP2017522852A JP2017533910A5 JP 2017533910 A5 JP2017533910 A5 JP 2017533910A5 JP 2017522852 A JP2017522852 A JP 2017522852A JP 2017522852 A JP2017522852 A JP 2017522852A JP 2017533910 A5 JP2017533910 A5 JP 2017533910A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
polypeptide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017522852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533910A (ja
JP6663428B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/058116 external-priority patent/WO2016069925A1/en
Publication of JP2017533910A publication Critical patent/JP2017533910A/ja
Publication of JP2017533910A5 publication Critical patent/JP2017533910A5/ja
Application granted granted Critical
Publication of JP6663428B2 publication Critical patent/JP6663428B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017522852A 2014-10-30 2015-10-29 Gdf15ポリペプチドを使用する、赤血球を増加させるための方法および組成物 Expired - Fee Related JP6663428B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462072889P 2014-10-30 2014-10-30
US62/072,889 2014-10-30
PCT/US2015/058116 WO2016069925A1 (en) 2014-10-30 2015-10-29 Methods and compositions using gdf15 polypeptides for increasing red blood cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020023090A Division JP7154241B2 (ja) 2014-10-30 2020-02-14 Gdf15ポリペプチドを使用する、赤血球を増加させるための方法および組成物

Publications (3)

Publication Number Publication Date
JP2017533910A JP2017533910A (ja) 2017-11-16
JP2017533910A5 true JP2017533910A5 (https=) 2018-12-06
JP6663428B2 JP6663428B2 (ja) 2020-03-11

Family

ID=55858354

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017522852A Expired - Fee Related JP6663428B2 (ja) 2014-10-30 2015-10-29 Gdf15ポリペプチドを使用する、赤血球を増加させるための方法および組成物
JP2020023090A Active JP7154241B2 (ja) 2014-10-30 2020-02-14 Gdf15ポリペプチドを使用する、赤血球を増加させるための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020023090A Active JP7154241B2 (ja) 2014-10-30 2020-02-14 Gdf15ポリペプチドを使用する、赤血球を増加させるための方法および組成物

Country Status (6)

Country Link
US (2) US10603359B2 (https=)
EP (2) EP3922259B1 (https=)
JP (2) JP6663428B2 (https=)
AU (2) AU2015339134B2 (https=)
CA (1) CA2964808C (https=)
WO (1) WO2016069925A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US10603359B2 (en) * 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
WO2017079591A2 (en) 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
KR102433503B1 (ko) * 2016-05-24 2022-08-18 노보 노르디스크 에이/에스 Mic-1 화합물 및 이것의 사용
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
EA202191105A1 (ru) 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
CA3161302A1 (en) * 2019-11-26 2021-06-03 Yuhan Corporation Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
US12209112B2 (en) * 2022-09-15 2025-01-28 The Chinese University Of Hong Kong Methods of preventing or treating diseases, conditions, or disorders associated with chemotherapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4965251A (en) 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
WO2000011168A2 (en) 1998-08-21 2000-03-02 Princeton University Genes that regulate hematopoietic blood forming stem cells and uses thereof
CN104524548A (zh) 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
JP5444363B2 (ja) * 2008-10-31 2014-03-19 セントビンセンツ ホスピタル シドニー リミテッド 慢性腎疾患における予後判定の方法
AU2010282361B2 (en) * 2009-08-13 2015-03-19 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
PH12013501969B1 (en) * 2011-03-29 2018-08-31 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of tmprss6 gene
EP3282257A1 (en) 2011-11-22 2018-02-14 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA3204283A1 (en) * 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
EP3683228A3 (en) 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
EP2644278B1 (en) 2012-03-27 2014-12-10 Alfa Laval Corporate AB Centrifugal separator and method of controlling intermittent discharge
ES2791183T3 (es) 2012-12-21 2020-11-03 Aveo Pharmaceuticals Inc Anticuerpos anti-GDF15
US9161966B2 (en) * 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
KR101993714B1 (ko) * 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
RS61778B1 (sr) * 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
JP2017509647A (ja) 2014-03-21 2017-04-06 アクセルロン ファーマ, インコーポレイテッド アクチビンbおよび/またはgdf11の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法
AU2015276800B2 (en) * 2014-06-20 2021-03-04 Aveo Pharmaceuticals, Inc. Treatment of chronic kidney disease and other renal dysfunction using a GDF15 modulator
US10603359B2 (en) * 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
TWI621976B (zh) 2015-07-24 2018-04-21 瑞鼎科技股份有限公司 內嵌式觸控面板驅動方法
US20170299608A1 (en) * 2016-03-04 2017-10-19 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight

Similar Documents

Publication Publication Date Title
JP2017533910A5 (https=)
JP2013501816A5 (https=)
RU2012109393A (ru) Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов
JP2015514115A5 (https=)
JP2017534638A5 (https=)
FI3352776T3 (fi) Htt-repressoreita ja niiden käyttötapoja
JP2016519138A5 (https=)
JP2012529436A5 (https=)
JP2017043632A5 (https=)
JP2014512171A5 (https=)
JP2018525416A5 (https=)
JP2016538885A5 (https=)
Samuel et al. Coadministration of adenoviral vascular endothelial growth factor and angiopoietin-1 enhances vascularization and reduces ventricular remodeling in the infarcted myocardium of type 1 diabetic rats
JP2018527941A5 (https=)
RU2016141055A (ru) Препараты арипипразола, имеющие повышенные скорости впрыска
EA201892366A1 (ru) Антисмысловые олигомеры и способы их применения для лечения заболеваний, связанных с геном кислой альфа-глюкозидазы
JP2018501791A5 (https=)
BR112020013519A2 (pt) método para tratamento de uma inflamação.
CA2574531A1 (en) Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
JP2018538261A5 (https=)
JP2019537446A5 (https=)
RU2015128078A (ru) Композиции и способы лечения рака мозга
JP2017523239A5 (https=)
JP2016501528A5 (https=)
WO2014036524A4 (en) Genetically modified msc and therapeutic methods